Skip To Main Content
Laercio Lopes DaSilva on Muck Rack

Laercio Lopes DaSilva

As seen in: JAMA Oncology, Chinese Clinical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Laercio Lopes

Contact Laercio Lopes, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis

|
By Felipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, Bruno Carvalho
| cco.amegroups.org
Original Article Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis Felipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, Ana Carolina Marin Comini, Bruno Murad Carvalho, Wilson Nogueira, Hyan Silveira, Brenda J. Ernst, Lida A. Mina
Open in Who Shared Issue with article?

Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis

|
By Felipe Batalini, Laercio Lopes DaSilva, Bruno Carvalho, Leticia Campoverde
| Chinese Clinical Oncology Verified
Original Article Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis Felipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, Ana Carolina Marin Comini, Bruno Murad Carvalho, Wilson Nogueira, Hyan Silveira, Brenda J. Ernst, Lida A. Mina
Open in Who Shared Issue with article?

Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis

|
By Felipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, Bruno Carvalho
| Chinese Clinical Oncology Verified
Highlight box Key findings • Patients with BRCA mutations benefit the most from PARPi, followed patients with HRD. • The benefit of PARPi in patients with HRP tumors is limited. What is known and what is new? • There are two HRD tests with different ways of evaluating genomic scars and a similar benefit of PARPi was found for patients with BRCA1/2 wild-type with gLOH-high and myChoice®+.
Open in Who Shared Issue with article?
See all 5 articles